title: The Metabolic Syndrome and Biochemical Recurrence following Radical Prostatectomy.
abstract: Metabolic syndrome refers to a set of conditions that increases the risk of cardiovascular disease and has been associated with an increased risk of prostate cancer, particularly among African American men. This study aimed to estimate the association of metabolic syndrome with biochemical recurrence (BCR) in a racially diverse population. Among 383 radical prostatectomy patients, 67 patients had documented biochemical recurrence. Hypertension was significantly, positively associated with the rate of BCR (hazard ratio (HR) = 2.1; 95%  CI = 1.1, 3.8). There were distinct racial differences in the prevalence of individual metabolic syndrome components; however, the observed associations with BCR did not differ appreciably by race. We conclude that hypertension may contribute to a poorer prognosis in surgically treated prostate cancer patients. Our findings suggest that targeting components of the metabolic syndrome which are potentially modifiable through lifestyle interventions may be a viable strategy to reduce risk of BCR in prostate cancer.
authors.affiliation: Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Post
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Beebe-Dimmer
authors.forename: Hal
authors.initials: H
authors.lastname: Morgenstern
authors.forename: Christine
authors.initials: C
authors.lastname: Neslund-Dudas
authors.forename: Cathryn H
authors.initials: CH
authors.lastname: Bock
authors.forename: Nora
authors.initials: N
authors.lastname: Nock
authors.forename: Andrew
authors.initials: A
authors.lastname: Rundle
authors.forename: Michelle
authors.initials: M
authors.lastname: Jankowski
authors.forename: Benjamin A
authors.initials: BA
authors.lastname: Rybicki
references.citation: Cancer Detect Prev. 2006;30(5):412-22
references.pmid: 17067754
references.citation: Ethn Dis. 2003 Fall;13(4):414-28
references.pmid: 14632261
references.citation: Cancer. 2007 Nov 15;110(10):2202-9
references.pmid: 17876838
references.citation: Arch Intern Med. 2008 Aug 11;168(15):1617-24
references.pmid: 18695075
references.citation: JAMA. 2002 Jan 16;287(3):356-9
references.pmid: 11790215
references.citation: Circulation. 2005 Mar 15;111(10):e134-9
references.pmid: 15769755
references.citation: Eur Urol. 2007 May;51(5):1175-84
references.pmid: 17240528
references.citation: J Urol. 1994 Nov;152(5 Pt 1):1358-68
references.pmid: 7523702
references.citation: Urology. 2002 Oct;60(4):670-4
references.pmid: 12385931
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5814-30
references.pmid: 16043830
references.citation: Cancer Causes Control. 2009 Jul;20(5):671-9
references.pmid: 19067188
references.citation: JAMA. 1999 May 5;281(17):1591-7
references.pmid: 10235151
references.citation: Cancer. 2007 Mar 1;109(5):875-81
references.pmid: 17265528
references.citation: J Urol. 2000 Jul;164(1):101-5
references.pmid: 10840432
references.citation: Ann Epidemiol. 2001 Nov;11(8):534-42
references.pmid: 11709272
references.citation: J Urol. 2003 Feb;169(2):517-23
references.pmid: 12544300
references.citation: J Urol. 2010 Mar;183(3):984-9
references.pmid: 20083281
references.citation: Urology. 2009 Jul;74(1):185-90
references.pmid: 19428088
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: Hypertension. 2004 Sep;44(3):248-52
references.pmid: 15262903
references.citation: JAMA. 2001 May 16;285(19):2486-97
references.pmid: 11368702
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):302-7
references.pmid: 17301263
references.citation: Diabetes. 1988 Dec;37(12):1595-607
references.pmid: 3056758
references.citation: Blood Press. 2004;13(1):47-55
references.pmid: 15083641
references.citation: Am J Clin Nutr. 2007 Sep;86(3):s843-57
references.pmid: 18265478
references.citation: Am J Epidemiol. 2006 Oct 15;164(8):769-74
references.pmid: 16952929